Genetic Testing for Liver Damage in Acute Lymphoblastic Leukemia
Pharmacogenomics of Asparaginase Induced Hepatotoxicity
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 500 (estimated)
- Sponsor
- University of Southern California · Other
This trial is looking for people who have just been diagnosed with acute lymphoblastic leukemia and will be receiving a treatment called asparaginase. Participants will provide saliva samples to help understand if certain genes affect how they might respond to this treatment.
You may be able to join if
- I have been diagnosed with acute lymphoblastic leukemia.
- I have not had any prior treatment for acute lymphoblastic leukemia.
- I will be receiving asparaginase as part of my treatment.
- I can understand and will sign a consent form.
- I received asparaginase between 2012 and 2017 and am a current patient at USC.
You may not be able to join if
- I am unable to give informed consent.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis pilot trial studies the impact of genetic information on developing liver damage caused by asparaginase in participants with newly diagnosed acute lymphoblastic leukemia. Testing saliva samples may help doctors find certain genetic markers that may predict whether participants will tolerate asparaginase, which is given as part of clinical care for acute lymphoblastic leukemia.
Loading trial locations…